AR030160A1 - Compuestos de acido hidroxamico , formulacion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de dicha composicion - Google Patents
Compuestos de acido hidroxamico , formulacion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de dicha composicionInfo
- Publication number
- AR030160A1 AR030160A1 ARP000104249A ARP000104249A AR030160A1 AR 030160 A1 AR030160 A1 AR 030160A1 AR P000104249 A ARP000104249 A AR P000104249A AR P000104249 A ARP000104249 A AR P000104249A AR 030160 A1 AR030160 A1 AR 030160A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- group
- hydroxamic acid
- formula
- manufacture
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 abstract 1
- 206010002329 Aneurysm Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 206010064996 Ulcerative keratitis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- -1 carrier Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000007717 corneal ulcer Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000003239 periodontal effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de ácido hidroxámico de formula 1 o una sal farmacéuticamente aceptable de la misma, dondeX se selecciona de OH, y NHOH; d es 1 o 2; R1 se selecciona de un grupo compuesto por aquellos denominados (a), (b), y otros de acuerdo con lo descrito en la memoria descriptiva, donde R2 es seleccionado de un grupo compuesto por H, y otros de acuerdo con lo descrito en la memoria descriptiva, R3 y R4 se selecciona de un grupo compuesto por alquilo de C1-20 y otros de acuerdo con la memoria descriptiva y de sustituyentes agrupados para formar un grupo de formula empírica -(CH2)sZg-, de acuerdo con la memoria descriptiva. Una formulacion farmacéutica que comprende un compuesto de ácido hidroxámico que es un compuesto de la formula 1 mezclado con un diluyente, vehículo, o excipiente del mismo. Uso de un compuesto de la formula 1 para la fabricacion de una composicion farmacéutica para inhibir una metaloproteinasa de matriz, la que se relaciona preferentemente con artritis, esclerosis multiple, aterosclerosis, restenosis, la inflamacion y el dolor, aneurisma, cardiopatía, osteoporosis, enfermedad periodontal, ulcera de cornea, ulcera decubital, cáncer, y desordenes neurodegenerativos cronicos y agudos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14966099P | 1999-08-18 | 1999-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030160A1 true AR030160A1 (es) | 2003-08-13 |
Family
ID=22531286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104249A AR030160A1 (es) | 1999-08-18 | 2000-08-17 | Compuestos de acido hidroxamico , formulacion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de dicha composicion |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6677355B1 (es) |
| EP (1) | EP1210326B1 (es) |
| JP (1) | JP2003507362A (es) |
| AR (1) | AR030160A1 (es) |
| AT (1) | ATE260251T1 (es) |
| AU (1) | AU6764400A (es) |
| BR (1) | BR0013390A (es) |
| CA (1) | CA2378332A1 (es) |
| CO (1) | CO5300407A1 (es) |
| DE (1) | DE60008548T2 (es) |
| DK (1) | DK1210326T3 (es) |
| ES (1) | ES2216938T3 (es) |
| MX (1) | MXPA01013324A (es) |
| PE (1) | PE20010486A1 (es) |
| PT (1) | PT1210326E (es) |
| TR (4) | TR200200410T2 (es) |
| UY (1) | UY26302A1 (es) |
| WO (1) | WO2001012592A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8088737B2 (en) | 2003-04-04 | 2012-01-03 | Incyte Corporation | Compositions, methods and kits relating to Her-2 cleavage |
| GB0326546D0 (en) * | 2003-11-14 | 2003-12-17 | Amersham Plc | Inhibitor imaging agents |
| PE20060426A1 (es) * | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| US7638513B2 (en) * | 2004-06-02 | 2009-12-29 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7488745B2 (en) * | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7504424B2 (en) * | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| AU2005275213A1 (en) | 2004-07-16 | 2006-02-23 | Schering Corporation | Hydantoin derivatives for the treatment of inflammatory disorders |
| PE20071240A1 (es) * | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
| CL2007003108A1 (es) | 2006-10-28 | 2008-07-18 | Methylgene Inc Envivo Pharmace | Compuestos derivados de n-hidroxiamida sustituida con heterociclos, inhibidores de histona desacetilasa; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad del grupo que consiste en enfermedad de huntington, |
| PE20090223A1 (es) * | 2007-05-04 | 2009-03-08 | Wyeth Corp | Compuestos triciclicos como inhibidores de metaloproteinasas matriciales |
| TW201024304A (en) | 2008-09-24 | 2010-07-01 | Schering Corp | Compounds for the treatment of inflammatory disorders |
| US8450355B2 (en) | 2008-09-24 | 2013-05-28 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory diseases |
| EP2356111A1 (en) | 2008-11-10 | 2011-08-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US8569336B2 (en) | 2008-11-10 | 2013-10-29 | Ling Tong | Compounds for the treatment of inflammatory disorders |
| BRPI0922938A2 (pt) * | 2008-12-05 | 2017-06-06 | Intermed Discovery Gmbh | inibidores de acúmulo de proteína hif-1 |
| BR112021006407A8 (pt) | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | uso de inibidores do egfr para ceratodermas |
| CN113336670B (zh) * | 2021-05-28 | 2023-06-02 | 河南大学 | 一种轴手性芴胺-苯酚类衍生物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
| ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
| PL334846A1 (en) | 1997-01-23 | 2000-03-27 | Hoffmann La Roche | Sulphamidic inhibitors of metaloproteases |
| HUP0002960A3 (en) * | 1997-08-08 | 2001-12-28 | Pfizer Prod Inc | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
-
2000
- 2000-08-10 AU AU67644/00A patent/AU6764400A/en not_active Abandoned
- 2000-08-10 TR TR2002/00410T patent/TR200200410T2/xx unknown
- 2000-08-10 AT AT00955435T patent/ATE260251T1/de not_active IP Right Cessation
- 2000-08-10 MX MXPA01013324A patent/MXPA01013324A/es active IP Right Grant
- 2000-08-10 DE DE60008548T patent/DE60008548T2/de not_active Expired - Fee Related
- 2000-08-10 ES ES00955435T patent/ES2216938T3/es not_active Expired - Lifetime
- 2000-08-10 WO PCT/US2000/021884 patent/WO2001012592A2/en active IP Right Grant
- 2000-08-10 TR TR2002/02164T patent/TR200202164T2/xx unknown
- 2000-08-10 DK DK00955435T patent/DK1210326T3/da active
- 2000-08-10 TR TR2002/02163T patent/TR200202163T2/xx unknown
- 2000-08-10 JP JP2001516893A patent/JP2003507362A/ja active Pending
- 2000-08-10 TR TR2002/02211T patent/TR200202211T2/xx unknown
- 2000-08-10 PT PT00955435T patent/PT1210326E/pt unknown
- 2000-08-10 BR BR0013390-6A patent/BR0013390A/pt not_active IP Right Cessation
- 2000-08-10 CA CA002378332A patent/CA2378332A1/en not_active Abandoned
- 2000-08-10 US US10/049,544 patent/US6677355B1/en not_active Expired - Fee Related
- 2000-08-10 EP EP00955435A patent/EP1210326B1/en not_active Expired - Lifetime
- 2000-08-17 PE PE2000000833A patent/PE20010486A1/es not_active Application Discontinuation
- 2000-08-17 UY UY26302A patent/UY26302A1/es not_active Application Discontinuation
- 2000-08-17 CO CO00061938A patent/CO5300407A1/es not_active Application Discontinuation
- 2000-08-17 AR ARP000104249A patent/AR030160A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20010486A1 (es) | 2001-04-20 |
| EP1210326A2 (en) | 2002-06-05 |
| TR200202211T2 (tr) | 2002-11-21 |
| US6677355B1 (en) | 2004-01-13 |
| TR200200410T2 (tr) | 2002-06-21 |
| WO2001012592A2 (en) | 2001-02-22 |
| AU6764400A (en) | 2001-03-13 |
| PT1210326E (pt) | 2004-07-30 |
| MXPA01013324A (es) | 2002-07-02 |
| DE60008548D1 (de) | 2004-04-01 |
| CA2378332A1 (en) | 2001-02-22 |
| DE60008548T2 (de) | 2004-08-05 |
| CO5300407A1 (es) | 2003-07-31 |
| DK1210326T3 (da) | 2004-06-21 |
| EP1210326B1 (en) | 2004-02-25 |
| BR0013390A (pt) | 2002-04-30 |
| JP2003507362A (ja) | 2003-02-25 |
| WO2001012592A3 (en) | 2001-07-05 |
| ES2216938T3 (es) | 2004-11-01 |
| TR200202164T2 (tr) | 2002-11-21 |
| ATE260251T1 (de) | 2004-03-15 |
| TR200202163T2 (tr) | 2002-11-21 |
| UY26302A1 (es) | 2000-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030160A1 (es) | Compuestos de acido hidroxamico , formulacion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de dicha composicion | |
| RU2001113733A (ru) | N-(2-арилпропионил) сульфонамиды и содержащие их фармацевтические препараты | |
| DK165003C (da) | Chlorsulfat | |
| UA74391C2 (uk) | Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти | |
| BG101308A (en) | Surfactant compositions | |
| ES8304072A1 (es) | "procedimiento de preparacion de derivados de 1-fenil-1-hidroxi-etilamina". | |
| UY27700A1 (es) | Compuestos oxo - azabiclícos. | |
| HUT55751A (en) | Process for producing 24-homo-d-vitamin derivatives and pharmaceutical compositions comprising same as active ingredient | |
| AR016134A1 (es) | Compuestos derivados de propil-amida o butil-indanilo, composicion farmaceutica que los contiene y su uso para la fabricacion de un medicamento con metalo-proteinasas inhibidoras de la agrecanasa y matriz extracelular eficaz en el tratamiento de la artritis | |
| ES2149305T3 (es) | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso. | |
| ES2038172T3 (es) | Procedimiento para preparar carboxamidas heterociclicas. | |
| AR022423A1 (es) | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento | |
| ES2078507T3 (es) | Medicinas y derivados de sulfonanilida. | |
| JPS6029400B2 (ja) | ジホスホノアルカンカルボン酸及びその製造法 | |
| FR2707089B1 (fr) | Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
| ATE338529T1 (de) | Haarpflegemittel, die phenolische haarformungsmittel enthalten | |
| ATE7295T1 (de) | 2-halo-pyridine, ihre herstellung und pharmazeutische zusammensetzungen. | |
| FR2455590A1 (fr) | Nouveaux derives d'acide 2-hydroxy-5-(1-hydroxy-2-piperazinylethyl)-benzoique, utiles notamment comme agents bloquants des recepteurs a- et b-adrenergiques, et leur procede de preparation | |
| AR007097A1 (es) | Biarilacetilenos inhibidores de la metaloproteasa de matriz, una composicion que tiene actividad inhibitoria de la metaloproteasa de matriz yel uso de dichos biarilacetilenos en la manufactura de un medicamento. | |
| ES2059348T3 (es) | Composicion farmaceutica para el tratamiento de cataratas. | |
| AR021491A1 (es) | Un compuesto de 6-azauracilo que inhibe a il-5, una composicion que lo comprende, un proceso para preparar dicha composicion, y el uso de dicho compuestopara la manufactura de un medicamento y de un agente de diagnostico | |
| AR007096A1 (es) | Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas | |
| FI903701A0 (fi) | Reninhaemmande amino-oligohydroxiderivat. | |
| SE8200649L (sv) | Polycykliska foreningar innehallande en dubbelbindning i d-ringen, sett for deras framstellning och farmaceutiska beredningar innehallande dem | |
| JPS5764639A (en) | Novel stilbene derivative, its preparation, and medical composition containing the same as active ingredent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |